AzTrials
AzTrials

PsoriasisPhase 3NCT04930042

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

A Phase 3 study testing Stelara and AVT04 in people with Psoriasis, run by Alvotech Swiss AG at 30 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Psoriasis
What is being tested?
Stelara and AVT04
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
581 participants
Where
30 sitesin 4 countries
Study dates
3 Jun 2021to 11 Oct 2022
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient has signed the informed consent form (ICF) and documentation as required by relevant competent authorities and is able to understand and adhere to the visit schedule and study requirements.
  • Chinese patients shall be recruited in Mainland China.
  • Patient is male or female, aged 18 to 75 years old, inclusive, at time of Screening.
  • Patient weighs ≤100 kg at Screening and at BL.
  • Patient has had moderate to severe chronic PsO for at least 6 months.
  • Patient has involved body surface area (BSA) ≥10%, PASI ≥12, and sPGA ≥3 (moderate) at Screening and at BL.
Show all 18Show fewer
  • Patient has had stable psoriatic disease for at least 2 months (ie, without significant changes as defined by the investigator or designee) prior to Screening.
  • Patient is a candidate for systemic therapy because the patient has had a previous failure, inadequate response, intolerance, or contraindication to at least 1 systemic antipsoriatic therapy including, but not limited to, methotrexate, cyclosporine, psoralen plus ultraviolet light A (PUVA), and ultraviolet light B (UVB).
  • Patient has a negative QuantiFERON test for tuberculosis (TB) during Screening.
  • Note: Patients with an indeterminate QuantiFERON test are allowed if they have all of the following:
  • No evidence of active TB on chest radiograph within 3 months prior to the first dose of study drug.
  • Documented history of adequate prophylaxis initiation prior to receiving study drug in accordance with local recommendations.
  • No known exposure to active TB after most recent prophylaxis.
  • Asymptomatic at Screening and BL. Investigators should check with the medical monitor before enrolling such patients.
  • Patient is naïve to ustekinumab therapy, approved or investigational.
  • Women of childbearing potential (except those who are postmenopausal for more than 2 years or if surgically sterile) must have a negative serum pregnancy test during Screening and negative urine pregnancy test at BL.
  • Sexually active women of childbearing potential must agree to use highly effective contraception (sterilization, hormonal contraception pills or injection or implants, and abstinence) for the duration of the study and until 4 months after the last dose of the study drug. Male patients must agree to use contraception for the duration of the study and agree not to donate sperm during and for 4 months after the last dose of study drug.
  • Note: Male partners of female subjects should also use contraception and should not donate sperm until 4 months after the last dose of study drug.

Who cannot join

  • Patient diagnosed with psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic autoimmune disorder inflammatory disease at the time of the Screening Visit that would interfere with evaluations of the effect of the study drug on psoriasis.
  • Patient has prior use of any of the following medications within specified time periods or will require use during the study:
  • Topical medications within 2 weeks of BL visit (except low- to mid-potency topical corticosteroids on face, eyes, scalp, palms, soles, and genital area; only).
  • PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the BL visit.
  • Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and acitretin) within 4 weeks prior to the BL visit.
  • Any systemic steroid in the 4 weeks prior to the BL visit.
Show all 37Show fewer
  • Any oral traditional Chinese medicine (TCM) 4 weeks prior to the BL visit or any topical TCM 2 weeks prior to the BL visit.
  • Investigational agent(s) within 90 days or 5 half-lives (whichever is longer) before BL visit.
  • Other systemic biologics within 90 days or 5 half-lives (whichever is the longer) before BL visit.
  • Any therapeutic agent targeting IL-12, IL-17 or IL-23 at any time. Specified washout periods for approved/marketed products are provided in Table 5.1.
  • Table 5.1: Approved/Marketed Products Medication or Therapy Washout before BL Biologic Therapies, including but limited to: Adalimumab Etanercept Secukinumab Infliximab Certolizumab pegol Alefacept Briakinumab Guselkumab Brodalumab 12 weeks 8 weeks 12 weeks 12 weeks 24 weeks 24 weeks 24 weeks 13 weeks 13 weeks Any kinase inhibitor for any reason (eg, tofacitinib citrate) 1 day Any phosphodiesterase type 4 inhibitor (eg, apremilast [Otezla]) 4 weeks Cyclosporine 4 weeks Methotrexate 4 weeks PUVA-UVA/UVB 4 weeks Topical psoriasis treatments (examples include vitamin D analogs, topical steroids, polifenols, etc) (except low- to mid-potency topical corticosteroids on face, eyes, scalp, palms, soles, and genital area; only) 2 weeks Oral retinoids 4 weeks Corticosteroids IM - IV - oral - intraarticular 4 weeks Drugs that may cause new onset or exacerbation of psoriasis (including, but not limited to, beta blockers, lithium, and anti-malarials) 6 months1 TCM (oral) TCM (topical) 4 weeks 2 weeks Abbreviations: BL = Baseline; IM = intramuscular; IV = intravenous; PUVA = psoralen plus ultraviolet light A; TCM = traditional Chinese medicine; UVA = ultraviolet light A; UVB = ultraviolet light B. 1 Unless the patient has been on a stable dose for at least 6 months prior to BL Visit without exacerbation of psoriasis.
  • Patient has received live or attenuated vaccines during the 4 weeks prior to BL visit or has the intention of receiving a live or attenuated vaccine at any time during the study.
  • Note: Inactivated (non-live and non-attenuated) vaccines are allowed.
  • Patient has an underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) which, in the opinion of the investigator or designee, significantly immunocompromises the patient and/or places the patient at unacceptable risk for receiving an immunomodulatory therapy.
  • Patient has a planned surgical intervention during the duration of the study except those related to the underlying disease and which, in the opinion of the investigator or designee, will not put the patient at further risk or hinder the patient's ability to maintain compliance with study drug and the visit schedule.
  • Patient has an active and serious infection or history of infections as follows:
  • Any active infection (including Severe Acute Respiratory Syndrome-Coronavirus-2 [SARS-CoV-2] infection) i. For which non-systemic anti-infectives were used within 4 weeks prior to BL visit. Note: patients receiving topical antibiotics for facial acne do not need to be excluded.
  • Which required hospitalization/quarantine or systemic anti-infective within 8 weeks prior to BL visit.
  • Recurrent or chronic infections or other active infection that, in the opinion of the investigator or designee, might cause this study to be detrimental to the patient.
  • Invasive fungal infection or mycobacterial infection. d. Opportunistic infections, such as listeriosis, legionellosis, or pneumocystis.
  • Patient is positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb).
  • Patient has severe progressive or uncontrolled, clinically significant disease that in the judgment of the investigator or designee renders the patient unsuitable for the study.
  • Patient has a history of malignancy within 5 years except for adequately treated cutaneous squamous or basal cell carcinoma, in situ cervical cancer or in situ breast ductal carcinoma.
  • Patient has active neurological disease such as multiple sclerosis, Guillain-Barré syndrome, optic neuritis, transverse myelitis, or history of neurologic symptoms suggestive of central nervous system demyelinating disease.
  • Patient has moderate to severe heart failure (New York Heart Association class III/IV).
  • Patient has uncontrolled diabetes mellitus type 1 or 2.
  • Patient has a history of hypersensitivity to the active substance or to any of the excipients of Stelara or AVT04.
  • Patient is pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation.
  • Patient has evidence (as assessed by the investigator or designee using good clinical judgment) of alcohol or drug abuse or dependency at the time of Screening, for the 5 years prior to Screening, or during the study.
  • Patient is unable to follow study instructions and comply with the protocol in the opinion of the investigator or designee.
  • Patient has a history of clinically significant hematological abnormalities, including cytopenia (eg, thrombocytopenia, leukopenia).
  • Patient has a laboratory abnormality that, in the opinion of the investigator or designee, could cause this study to be detrimental to the patient. The following laboratory abnormalities should be excluded:
  • Hemoglobin <9 g/dL
  • Platelet count <100,000/mm³
  • White blood cell count <3000 cells/mm³
  • Aspartate aminotransferase and/or alanine aminotransferase that is persistently ≥2 × the upper limit of normal. (Persistently indicates at least on 2 occasions separated by a number of days, per the rescreening procedure)
  • Creatinine clearance <50 mL/min (Cockcroft-Gault formula)

Trial locations and contacts

30 sites in 4 countries.

30 sites in 4 countries

Poland14 sites

  • ClinicMed Daniluk, Nowak Spolka Jawna

    Bialystok, 15879

  • Centrum Badan Klinicznych PI-House Sp. Z o.o

    Gdansk, 80546

  • Centrum Medyczna ALL-MED

    Krakow, 30033

  • SGD SC

    Krakow, 31147

  • DERMED Centrum Medyczne Sp. z o.o.

    Lodz, 90265

  • Dermoklinika Centrum Medyczne s.c. M.Kierstan, J. Narbutt, A. Lesiak

    Lodz, 90436

  • ETYKA Osrodek Badan Klinicznych

    Olsztyn, 11041

  • Kliniczny Szpital Wojewódzki Nr. 1 im. Fryderyka Chopina, Klinika Detmatologii

    Rzeszów, 35055

  • MICS Centrum Medyczne Toruń

    Torun, 87100

  • Medycyna Kliniczna

    Warsaw, 00874

  • Klinika Ambroziak Dermatologia

    Warsaw, 02953

  • Royalderm Agnieszka Nawrocka

    Warsaw, 02962

  • DermMedica Sp. z o.o

    Wroclaw, 51318

  • WroMedica I. Bielicka, A. Strzalkowska s.c.

    Wroclaw, 51685

Other trials in Poland

Ukraine7 sites

  • Communal nonprofit enterprise ,,City Dermatovenereological Dispensary #2,, Kharkiv city council

    Kharkiv, 61038

  • Private Medical Center Medical Clinic Blagomed LLC

    Kyiv, 01023

  • National Medical University named after O.O.Bohomolets

    Kyiv, 01601

  • Treatment and Diagnostic Center of private enterprise "Asclepius"

    Lviv, 79000

  • Municipal Enterprise "Rivne Regional Dermatology and Venereology Dispensary" of Rivne Regional Council

    Rivne, 33028

  • Treatment and Diagnostic Center of private enterprise "Asclepius"

    Uzhhorod, 88000

  • Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Eastern Region

    Zaporizhzhya, 69063

Other trials in Ukraine

Georgia6 sites

  • Aleksandre Aladashvili Clinic, LLC

    Tbilisi, 0102

  • J.S.C. Curatio

    Tbilisi, 0114

  • LEPL The First University Clinic of Tbilisi State Medical University

    Tbilisi, 0141

  • Scientific Research National Center of Dermatology and Venereology LLC

    Tbilisi, 0159

  • Health Institute LLC

    Tbilisi, 0160

  • David Abuladze Georgian-Italian Clinic LTD

    Tbilisi, 0179

Other trials in Georgia

Estonia3 sites

  • North Estonia Medical Centre

    Tallinn, 13419

  • Innomedica OU

    Tallinn

  • Tartu University Hospital

    Tartu, 50406

Other trials in Estonia

About this study

Official title: A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Ustekinumab (AVT04) and Stelara® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis

Read the detailed description

AVT04 is a fully human immunoglobulin class G1κ monoclonal antibody that specifically binds to the shared p40 protein subunit of IL-12 and IL-23 and therefore inhibits their activites

AVT04 is being developed to be a biosimilar with the European Union (EU)-licensed drug Stelara® (hereafter referred to as Stelara) ustekinumab, Anatomical Therapeutic Chemical code: L04AC05) injection for subcutaneous (SC) and intravenous use. Stelara is an anti-IL-12 and anti-IL-23 monoclonal antibody approved for various indications. Indications approved in the EU11 and United States (US)12 include: PsO in adult and pediatric patients, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Indications approved in the People's Republic of China include PsO and Crohn's disease.13 Approval status may differ in other geographic regions.

This is a multicenter, double-blind, randomized, active control clinical study to compare the efficacy, safety, and immunogenicity of AVT04 versus Stelara in patients with moderate to severe chronic PsO.

The active period of Study AVT04-GL-301 comprises 2 stages:

  • Stage 1: Primary Efficacy Assessment (Day 1 to Week 15)
  • Stage 2: Long Term Efficacy and Safety Assessment (Week 16 to 52) Stage 1 On Day 1, after successfully completing Screening activities, eligible patients will be randomized into Groups 1 and 2, in a 1:2 ratio (AVT04:Stelara), and begin Stage 1.

Patient randomization will be stratified by presence or absence of previous biologic treatment, by region; ie, Europe or China, and by body weight category (≤80 kg vs >80 kg).

  • Group 1: Patients will receive an initial dose of AVT04 45 mg administered SC, followed by 45 mg 4 weeks later.
  • Group 2: Patients will receive an initial loading dose of Stelara, 45 mg administered SC, followed by 45 mg 4 weeks later.

Stage 2

At Week 16:

Patients who were initially randomized in Group 1 (AVT04) will continue to receive AVT04 45 mg SC every 12 weeks at Weeks 16, 28, and 40 (unless withdrawn from the study).

Patients who were initially randomized in Group 2 (Stelara) will be re-randomized into Groups 2A and 2B, in a 1:1 ratio:

  • Group 2A: Patients will begin receiving AVT04 45 mg SC every 12 weeks, at Weeks 16, 28, and 40 (unless withdrawn from the study).
  • Group 2B: Patients will continue to receive Stelara 45 mg SC every 12 weeks, at Weeks 16, 28, and 40 (unless withdrawn from the study).

At Week 28:

  • Non-responsive patients (PASI improvement <50% compared to BL) will be encouraged to continue in the study for safety analyses, per the Schedule of Assessments (SoA) (Table 7.1), but will not receive further study drug.
  • Responsive patients (PASI improvement ≥50% compared to BL) will continue in the study.

At Week 40: All patients who are still in the study (except Week 28 non-responsive patients) will receive the final study drug administration.

At Week 52 (EoS/ET): All patients will undergo final efficacy and safety assessment.

Conditions
Psoriasis
Being tested
Stelara, AVT04
Medical subject headings
Psoriasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • StelaraDrug

    AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12

  • AVT04Drug

    AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12

Study groups in NCT04930042
Study groupRoleWhat they receive
AVT04 45 mg SCExperimentalTest Product: AVT04 (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
Receives: Drug: AVT04
EU Stelara 45 mg SCActive comparatorComparator ref product: EU Stelara (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
Receives: Drug: Stelara

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Psoriasis Area and Severity Index (PASI)

    Percent (%) change in Psoriasis Area and Severity Index (PASI)

    Measured: Baseline to week 12

Secondary outcomes (2)

  1. PASI 50, 75, 90 and 100 response rates

    PASI 50, 75, 90, and 100 response rates at Weeks 4, 8, 12, 16, 28, 40, and 52 (EoS/ET)

    Measured: Baseline to week 52

  2. PASI percent improvement

    Percent improvement in PASI from BL to Week 4, 8, 16, 28, 40, and 52 (EoS/ET).

    Measured: Baseline to week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2021
  2. Study start3 Jun 2021
  3. Primary completion28 Dec 2021
  4. Study completion11 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
581 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04930042
Sponsor's protocol ID
AVT04-GL-301
Status last verified
May 2022
First submitted
19 Jan 2021
Last updated
2 Feb 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Feldman SR, Reznichenko N, Berti F, Duijzings P, Ruffieux R, Otto H, Haliduola HN, Leutz S, Stroissnig H. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):759-771. doi: 10.1080/14712598.2023.2235263. Epub 2023 Jul 12.

    PubMed 37435850

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Stelara and AVT04 in people with Psoriasis, run by Alvotech Swiss AG at 30 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 30 sites in Poland, Ukraine, Georgia, Estonia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Psoriasis Area and Severity Index (PASI) (time frame: Baseline to week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04930042, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in